CIRCA-MED WP1 & WP3 - Circadian Rhythms in ICU Patients
Retrospective Characterization of Circadian Rhythms Using Vital Signs and Other Routine Data From Patients in the Intensive Care Unit
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Berlin, Germany, 10117
- Institute of Medical Informatics, Charite University, Berlin
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
Primary Retrospective Cohort:
- Admitted to and treated in a participating Intensive Care Unit (ICU) between 2017 and 2024
- Minimum ICU length of stay of 3 days (≥ 72 hours)
- Age ≥ 18 years at the time of ICU admission
- All genders (male, female, diverse)
Cohorts from previous studies:
- Prior enrollment in one of the designated parent study protocols
- Availability of supplementary biological or metabolic data (e.g., clock gene expression, melatonin levels) suitable for exploratory association analyses
Exclusion Criteria:
- None
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
All retrospective patients between 2017 and 2024
Relates to retrospective data from all patients who spent at least three days in participating intensive care units at Charite University, Berlin, Germany between 2017 and 2024
|
These are the primary exposures and are used to detect oscillatory patterns and characterize circadian rhythms.
They include heart rate, body temperature, blood pressure, blood glucose, and insulin.
These are secondary exposures that may influence circadian rhythms: illness severity (e.g., Sequential Organ Failure Assessment (SOFA) score), sedation levels, organ support therapies (e.g., ventilation, dialysis, Extracorporeal Membrane Oxygenation (ECMO)), and medications administered during ICU stay (e.g., sedatives, vasopressors, corticosteroids).
These exposures represent complications that may be associated with circadian disruption: delirium, deep sedation, ICU-acquired muscle weakness, and post-intensive care syndrome.
|
|
Pa-COVID (DRKS00021688)
|
These are the primary exposures and are used to detect oscillatory patterns and characterize circadian rhythms.
They include heart rate, body temperature, blood pressure, blood glucose, and insulin.
These are secondary exposures that may influence circadian rhythms: illness severity (e.g., Sequential Organ Failure Assessment (SOFA) score), sedation levels, organ support therapies (e.g., ventilation, dialysis, Extracorporeal Membrane Oxygenation (ECMO)), and medications administered during ICU stay (e.g., sedatives, vasopressors, corticosteroids).
These exposures represent complications that may be associated with circadian disruption: delirium, deep sedation, ICU-acquired muscle weakness, and post-intensive care syndrome.
These exposures reflect biological clock function: clock gene expression (if available in some cases), and melatonin levels.
|
|
SeptiCLOCK (NCT02044575)
|
These are the primary exposures and are used to detect oscillatory patterns and characterize circadian rhythms.
They include heart rate, body temperature, blood pressure, blood glucose, and insulin.
These are secondary exposures that may influence circadian rhythms: illness severity (e.g., Sequential Organ Failure Assessment (SOFA) score), sedation levels, organ support therapies (e.g., ventilation, dialysis, Extracorporeal Membrane Oxygenation (ECMO)), and medications administered during ICU stay (e.g., sedatives, vasopressors, corticosteroids).
These exposures represent complications that may be associated with circadian disruption: delirium, deep sedation, ICU-acquired muscle weakness, and post-intensive care syndrome.
These exposures reflect biological clock function: clock gene expression (if available in some cases), and melatonin levels.
|
|
VITALITY (NCT02143661)
|
These are the primary exposures and are used to detect oscillatory patterns and characterize circadian rhythms.
They include heart rate, body temperature, blood pressure, blood glucose, and insulin.
These are secondary exposures that may influence circadian rhythms: illness severity (e.g., Sequential Organ Failure Assessment (SOFA) score), sedation levels, organ support therapies (e.g., ventilation, dialysis, Extracorporeal Membrane Oxygenation (ECMO)), and medications administered during ICU stay (e.g., sedatives, vasopressors, corticosteroids).
These exposures represent complications that may be associated with circadian disruption: delirium, deep sedation, ICU-acquired muscle weakness, and post-intensive care syndrome.
These exposures reflect biological clock function: clock gene expression (if available in some cases), and melatonin levels.
|
|
TRG-N (ISRCTN77569430)
|
These are the primary exposures and are used to detect oscillatory patterns and characterize circadian rhythms.
They include heart rate, body temperature, blood pressure, blood glucose, and insulin.
These are secondary exposures that may influence circadian rhythms: illness severity (e.g., Sequential Organ Failure Assessment (SOFA) score), sedation levels, organ support therapies (e.g., ventilation, dialysis, Extracorporeal Membrane Oxygenation (ECMO)), and medications administered during ICU stay (e.g., sedatives, vasopressors, corticosteroids).
These exposures represent complications that may be associated with circadian disruption: delirium, deep sedation, ICU-acquired muscle weakness, and post-intensive care syndrome.
These exposures reflect biological clock function: clock gene expression (if available in some cases), and melatonin levels.
These exposures represent metabolic consequences of critical illness: insulin sensitivity, muscle atrophy, and critical illness myopathy or ICU-acquired weakness.
|
|
CIPCIM2 (ISRCTN19392591)
|
These are the primary exposures and are used to detect oscillatory patterns and characterize circadian rhythms.
They include heart rate, body temperature, blood pressure, blood glucose, and insulin.
These are secondary exposures that may influence circadian rhythms: illness severity (e.g., Sequential Organ Failure Assessment (SOFA) score), sedation levels, organ support therapies (e.g., ventilation, dialysis, Extracorporeal Membrane Oxygenation (ECMO)), and medications administered during ICU stay (e.g., sedatives, vasopressors, corticosteroids).
These exposures represent complications that may be associated with circadian disruption: delirium, deep sedation, ICU-acquired muscle weakness, and post-intensive care syndrome.
These exposures reflect biological clock function: clock gene expression (if available in some cases), and melatonin levels.
These exposures represent metabolic consequences of critical illness: insulin sensitivity, muscle atrophy, and critical illness myopathy or ICU-acquired weakness.
|
|
CGM (NCT02296372)
|
These are the primary exposures and are used to detect oscillatory patterns and characterize circadian rhythms.
They include heart rate, body temperature, blood pressure, blood glucose, and insulin.
These are secondary exposures that may influence circadian rhythms: illness severity (e.g., Sequential Organ Failure Assessment (SOFA) score), sedation levels, organ support therapies (e.g., ventilation, dialysis, Extracorporeal Membrane Oxygenation (ECMO)), and medications administered during ICU stay (e.g., sedatives, vasopressors, corticosteroids).
These exposures represent complications that may be associated with circadian disruption: delirium, deep sedation, ICU-acquired muscle weakness, and post-intensive care syndrome.
|
|
HELIA-ICU (NCT05556811)
|
These are the primary exposures and are used to detect oscillatory patterns and characterize circadian rhythms.
They include heart rate, body temperature, blood pressure, blood glucose, and insulin.
These are secondary exposures that may influence circadian rhythms: illness severity (e.g., Sequential Organ Failure Assessment (SOFA) score), sedation levels, organ support therapies (e.g., ventilation, dialysis, Extracorporeal Membrane Oxygenation (ECMO)), and medications administered during ICU stay (e.g., sedatives, vasopressors, corticosteroids).
These exposures represent complications that may be associated with circadian disruption: delirium, deep sedation, ICU-acquired muscle weakness, and post-intensive care syndrome.
These exposures reflect biological clock function: clock gene expression (if available in some cases), and melatonin levels.
|
|
PICS-Analyse (EA1/229/24)
|
These are the primary exposures and are used to detect oscillatory patterns and characterize circadian rhythms.
They include heart rate, body temperature, blood pressure, blood glucose, and insulin.
These are secondary exposures that may influence circadian rhythms: illness severity (e.g., Sequential Organ Failure Assessment (SOFA) score), sedation levels, organ support therapies (e.g., ventilation, dialysis, Extracorporeal Membrane Oxygenation (ECMO)), and medications administered during ICU stay (e.g., sedatives, vasopressors, corticosteroids).
These exposures represent complications that may be associated with circadian disruption: delirium, deep sedation, ICU-acquired muscle weakness, and post-intensive care syndrome.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Characterization of circadian periodicities and classification of time-varying patterns based on routine clinical data
Time Frame: From ICU admission to ICU discharge or death, whichever comes first (expected average duration of 4 weeks).
|
Assessment of periodicities and time-varying patterns in routine clinical parameters, including heart rate, body temperature, blood pressure, blood glucose, and insulin levels.
Time-series analysis will be conducted to extract continuous metrics (amplitude, period, and phase).
Based on these metrics, patients will be classified into distinct categorical groups according to their periodic oscillation profiles.
|
From ICU admission to ICU discharge or death, whichever comes first (expected average duration of 4 weeks).
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Association between circadian rhythm category and clinical severity scores
Time Frame: From ICU admission to ICU discharge or death, whichever comes first (expected average duration of 4 weeks).
|
Relationship between circadian rhythm classification and illness severity (e.g., SOFA score), sedation level, and use of organ support therapies.
|
From ICU admission to ICU discharge or death, whichever comes first (expected average duration of 4 weeks).
|
|
Association between circadian rhythm disruption and critical illness-related conditions
Time Frame: From ICU admission to ICU discharge or death, whichever comes first (expected average duration of 4 weeks), and post-ICU period (up to 3 and 6 months).
|
Presence of delirium, ICU-acquired muscle weakness/critical illness myopathy, and PICS in relation to circadian rhythm category.
Delirium will be measured with the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU) binary scale (Positive/Negative).
|
From ICU admission to ICU discharge or death, whichever comes first (expected average duration of 4 weeks), and post-ICU period (up to 3 and 6 months).
|
|
Association between time-varying clinical patterns and external biological markers (from other studies)
Time Frame: Depending on individual study protocols, from ICU admission through 24 months post-discharge. Sampled daily to weekly during the ICU stay, followed by post-discharge examinations conducted at variable monthly intervals (a maximum of 5 visits).
|
Exploratory associations between oscillatory trends in routine clinical data and biological markers reported in other studies, such as clock gene expression, melatonin levels, insulin sensitivity, muscle atrophy, and critical illness myopathy.
Only associations will be evaluated.
|
Depending on individual study protocols, from ICU admission through 24 months post-discharge. Sampled daily to weekly during the ICU stay, followed by post-discharge examinations conducted at variable monthly intervals (a maximum of 5 visits).
|
|
Feasibility and Data Infrastructure for Real-Time Circadian Visualization (Chrono-Apps)
Time Frame: From ICU admission to ICU discharge or death, whichever comes first (expected average duration of 4 weeks).
|
Evaluation of the technical feasibility and data integration requirements for generating real-time circadian visualizations within the Patient Data Management System (PDMS).
Feasibility will be assessed based on data completeness, sampling frequency compliance, latency of time-series data streaming from routine ICU monitors, and system stability required to display continuous circadian profiles via Chrono-Apps.
|
From ICU admission to ICU discharge or death, whichever comes first (expected average duration of 4 weeks).
|
|
Performance of Algorithm-Based Light Therapy Recommendations
Time Frame: From ICU admission to ICU discharge or death, whichever comes first (expected average duration of 4 weeks).
|
Retrospective evaluation of the accuracy and stability of the time-series analysis designed to estimate circadian phase of routine clinical data (vital signs) and generate individualized lighting schedules.
|
From ICU admission to ICU discharge or death, whichever comes first (expected average duration of 4 weeks).
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- EA1/284/22
- 541063275 - TRR 418 (Other Grant/Funding Number: Deutsche Forschungsgemeinschaft (DFG, German Research Foundation))
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.